New Clinical Guidelines Restrict Hormone Use to Treat Deficiency, Not Performance
The updated clinical policy states that testosterone replacement may be prescribed only when a clear medical diagnosis of hypogonadism is established. It does not support hormone therapy as a means to improve battlefield performance or physical endurance.
Medical officers must first evaluate service members for symptom clusters and risk factors before ordering laboratory testing. A positive evaluation triggers two separate fasting blood samples. Persistent low readings, together with the symptom profile, are required for a formal diagnosis.
If the total testosterone values are within normal limits, further testing may be considered only if symptoms persist, but therapy will not be approved. The policy also notes that there is no scientific evidence linking testosterone supplementation to enhanced cognition, energy levels, or overall combat effectiveness.